Efficacy of Faviprevir in COVID-19 Treatment

Official Title

Clinical Study Evaluating the Efficacy of Faviprevir in COVID-19 Treatment

Brief Summary

Faviprevir in COVID-19 treatment

Detailed Description

Clinical Study Evaluating the Efficacy of Faviprevir in COVID-19 treatment

Status

Completed

Conditions

COVID

Interventions

Drug: Favipiravir

Favipiravir
Other Name: Faviprevir

Drug: Chloroquine

chloroquine oral tablets

Eligibility Criteria

Inclusion Criteria:

- Patients with covid 19

Exclusion Criteria:

- Allergy or contraindications to faviprevir

Eligibility Gender

All

Eligibility Age

Minimum: 18 Years ~ Maximum: 80 Years

Countries

Egypt

Locations

Tanta University, Ainshams University
Tanta, Egypt

Investigators

sherief Abd-Elsalam, Ass. Prof., Principal Investigator
Tanta University - Faculty of Medicine

NCT Number

NCT04351295

MeSH Terms

Chloroquine

Favipiravir

Disclaimer:

Expanded Access program information for companies listed in the Expanded Access Company Directory is pulled daily from ClinicalTrials.gov, a resource provided by the National Institutes of Health in cooperation with the U.S. Food and Drug Administration. Click here for more information about ClinicalTrials.gov.

(202) 849 - 2075

1333 New Hampshire Ave, NW
Suite 420
Washington, DC 20036

navigator@reaganudall.org

Disclaimer:

Subscribe for updates from the Reagan-Udall Foundation for the FDA